A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Michael J MorrisM A Carducci

Abstract

This first-in-human phase I/IIA study was designed to evaluate the safety and pharmacokinetics (PKs) of AGS-PSCA a fully human monoclonal antibody directed to prostate stem cell antigen (PSCA) in progressive castration-resistant prostate cancer. Twenty-nine patients were administered infusions of AGS-PSCA (1-40 mg/kg) every 3 weeks for 12 weeks; 18 final patients received a 40-mg/kg loading dose followed by 20-mg/kg repeat doses. Primary end points were safety and PK. Immunogenicity, antitumor activity and circulating tumor cells were also evaluated. No drug-related serious adverse events were noted. Dose escalation stopped before reaching the maximum tolerated dose as target concentrations were achieved. Drug levels accumulated linearly with dose and the mean terminal half-life was 2-3 weeks across dose levels. The 40-mg/kg loading dose followed by repeated 20-mg/kg doses yielded serum drug concentrations above the projected minimum therapeutic threshold after two to three doses without excessive drug accumulation or toxicity. Significant antitumor effects were not seen. A 40-mg/kg loading dose followed by 20-mg/kg infusions every 3 weeks is the recommended phase II dose of AGS-PSCA. PSCA is a promising drug target and studies...Continue Reading

References

Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·R E ReiterO N Witte
Feb 28, 2001·Proceedings of the National Academy of Sciences of the United States of America·D C SaffranA Jakobovits
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Apr 9, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John S LamRobert E Reiter
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johann S de BonoDerek Raghavan
May 27, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Norihisa SaekiXifeng Wu
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Jul 26, 2011·Seminars in Oncology Nursing·Seth Wolpin, Mark Stewart
Nov 15, 2011·The Journal of Urology·Patrick C Walsh

❮ Previous
Next ❯

Citations

Mar 2, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B M WolpinM Hidalgo
Dec 26, 2012·Journal of the National Cancer Institute·Indu KohaarLudmila Prokunina-Olsson
Nov 8, 2016·Expert Opinion on Biological Therapy·Panagiotis J VlachostergiosScott T Tagawa
Jan 25, 2017·Cancers·Damien A Leach, Grant Buchanan
May 31, 2018·Stem Cells·Sergej SkvortsovAnna Dubrovska
Oct 24, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Neda KhaliliNima Rezaei
Jul 22, 2016·The Oncologist·Emilie M J van BrummelenJan H M Schellens
Dec 7, 2013·Expert Review of Anticancer Therapy·Xueling YangWei Tian
Sep 22, 2020·Therapeutic Advances in Urology·Shivani HandaAshutosh Tewari
Dec 11, 2013·Expert Review of Anticancer Therapy·Pedro Bargão Santos, Hitendra Rh Patel
Sep 16, 2015·Oncotarget·Akintunde AkinleyeDelong Liu
Apr 16, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Malwina CzerwińskaAnna Lankoff
Dec 10, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sinan WangJiang He
May 6, 2019·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Jorge A CarrasquilloMichael J Morris
Jun 27, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D Raghavan
Jul 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B M WolpinM Hidalgo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.